<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Multiple myeloma: Treatment of third or later relapse
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Multiple myeloma: Treatment of third or later relapse
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Multiple myeloma: Treatment of third or later relapse
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Author:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Jacob P Laubach, MD, MPP
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            S Vincent Rajkumar, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Rebecca F Connor, MD
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Dec 20, 2023.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H2538233890">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         There are many treatment options for relapsed or refractory multiple myeloma (MM). Most patients experience serial relapse and will be treated with most available agents at some point during their disease course. The choice of therapy at each relapse is informed by prior therapies used, response to these treatments, comorbidities, and disease aggressiveness.
        </p>
        <p>
         Treatment of MM in third or later relapse will be discussed here. Many of the regimens used for first or second relapse may also be appropriate if not utilized previously. General principles for the management of relapsed or refractory MM, the management of first or second relapse, administration considerations for common therapies, and the use of autologous and allogeneic hematopoietic cell transplantation are discussed separately.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/6643.html" rel="external">
          "Multiple myeloma: Overview of management"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/121127.html" rel="external">
          "Multiple myeloma: Treatment of first or second relapse"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/6647.html" rel="external">
          "Multiple myeloma: Initial treatment"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/131450.html" rel="external">
          "Multiple myeloma: Administration considerations for common therapies"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/6656.html" rel="external">
          "Multiple myeloma: Use of hematopoietic cell transplantation"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3523810048">
         <span class="h1">
          ASSESS DRUG SENSITIVITY
         </span>
         <span class="headingEndMark">
          —
         </span>
         The choice of therapy for relapsed MM must consider prior therapy, response, and likelihood of the disease being sensitive or refractory to prior agents  (
         <a class="graphic graphic_algorithm graphicRef134484" href="/z/d/graphic/134484.html" rel="external">
          algorithm 1
         </a>
         ). In general, refractory disease is defined as progressing on or within 60 days of receiving standard doses of a specific therapy.
        </p>
        <p>
         As an example, MM progressing on or within 60 days of receiving standard doses of
         <a class="drug drug_general" data-topicid="9822" href="/z/d/drug information/9822.html" rel="external">
          lenalidomide
         </a>
         (eg, 25 mg daily) is refractory to lenalidomide. In contrast, disease progression in a patient that previously received lenalidomide but not within the past 60 days or in a patient on a maintenance dose of single-agent lenalidomide (eg, 10 mg daily) is considered lenalidomide sensitive. Lenalidomide-sensitive MM may respond to a regimen that increases the dose of lenalidomide, reintroduces
         <a class="drug drug_general" data-topicid="9334" href="/z/d/drug information/9334.html" rel="external">
          dexamethasone
         </a>
         , and/or adds a third agent (eg, a monoclonal antibody or a proteasome inhibitor).
        </p>
        <p>
         The term penta-refractory disease is used for MM refractory to all of the following:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         An anti-CD38 monoclonal antibody (eg, daratumumab, isatuximab)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Lenalidomide
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Pomalidomide
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Bortezomib
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Carfilzomib
        </p>
        <p>
        </p>
        <p>
         Whether a patient has penta-refractory disease represents an important determinant of therapy in third or greater relapse, since the drugs that define penta-refractory MM are some of our most active agents in MM, and the regulatory approval of several other therapies has been limited to this specific population. Our approach is therefore structured according to whether or not the patient has penta-refractory MM.
        </p>
        <p class="headingAnchor" id="H3263402343">
         <span class="h1">
          NON-PENTA-REFRACTORY DISEASE
         </span>
         <span class="headingEndMark">
          —
         </span>
         For most patients with MM in third or greater relapse who maintain sensitivity to these agents, we suggest combination therapy that contains an agent among the following, to which the patient has not already become refractory:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         An anti-CD38 monoclonal antibody (eg, daratumumab, isatuximab)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Lenalidomide
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Pomalidomide
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Bortezomib
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Carfilzomib
        </p>
        <p>
        </p>
        <p>
         This recommendation is based on evidence derived from prospective trials evaluating these regimens containing one or more of these agents in patients with relapsed MM who received one to three prior lines of therapy. This approach also ensures patients with disease that is sensitive to these agents derive maximum benefit from them before receiving other agents in subsequent lines of treatment. The trials that have evaluated these combinations are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/121127.html" rel="external">
          "Multiple myeloma: Treatment of first or second relapse"
         </a>
         .)
        </p>
        <p>
         The choice of regimen is similar to that in first or second relapse, and it is driven by an understanding of drug sensitivity and expected toxicity  (
         <a class="graphic graphic_algorithm graphicRef134483" href="/z/d/graphic/134483.html" rel="external">
          algorithm 2
         </a>
         ). Accompanying tables provide active drugs by class  (
         <a class="graphic graphic_table graphicRef121137" href="/z/d/graphic/121137.html" rel="external">
          table 1
         </a>
         ), and major toxicities of selected treatment regimens  (
         <a class="graphic graphic_table graphicRef108257" href="/z/d/graphic/108257.html" rel="external">
          table 2
         </a>
         ).
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Daratumumab, pomalidomide, and dexamethasone (DPd) – (See
         <a class="medical medical_review" href="/z/d/html/121127.html" rel="external">
          "Multiple myeloma: Treatment of first or second relapse", section on 'Daratumumab, pomalidomide, dexamethasone (DPd)'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Isatuximab, pomalidomide, and dexamethasone (IsaPd) – (See
         <a class="medical medical_review" href="/z/d/html/121127.html" rel="external">
          "Multiple myeloma: Treatment of first or second relapse", section on 'Isatuximab, pomalidomide, dexamethasone (IsaPd)'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Elotuzumab, pomalidomide, and dexamethasone (EPd) – (See
         <a class="medical medical_review" href="/z/d/html/121127.html" rel="external">
          "Multiple myeloma: Treatment of first or second relapse", section on 'Elotuzumab, pomalidomide, dexamethasone (EPd)'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Carfilzomib, pomalidomide, and dexamethasone (KPd) – (See
         <a class="medical medical_review" href="/z/d/html/121127.html" rel="external">
          "Multiple myeloma: Treatment of first or second relapse", section on 'Carfilzomib, pomalidomide, dexamethasone (KPd)'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Bortezomib, pomalidomide, and dexamethasone (VPd) – (See
         <a class="medical medical_review" href="/z/d/html/121127.html" rel="external">
          "Multiple myeloma: Treatment of first or second relapse", section on 'Bortezomib, pomalidomide, dexamethasone (VPd)'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Bortezomib, cyclophosphamide, and dexamethasone (VCd) – (See
         <a class="medical medical_review" href="/z/d/html/121127.html" rel="external">
          "Multiple myeloma: Treatment of first or second relapse", section on 'Bortezomib, cyclophosphamide, dexamethasone (VCd)'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Daratumumab, carfilzomib, and dexamethasone (DKd) – (See
         <a class="medical medical_review" href="/z/d/html/121127.html" rel="external">
          "Multiple myeloma: Treatment of first or second relapse", section on 'Daratumumab, carfilzomib, dexamethasone (DKd)'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Isatuximab, carfilzomib, and dexamethasone (IsaKd) – (See
         <a class="medical medical_review" href="/z/d/html/121127.html" rel="external">
          "Multiple myeloma: Treatment of first or second relapse", section on 'Isatuximab, carfilzomib, dexamethasone (IsaKd)'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Selinexor, bortezomib, and dexamethasone (SVd) – (See
         <a class="medical medical_review" href="/z/d/html/121127.html" rel="external">
          "Multiple myeloma: Treatment of first or second relapse", section on 'Selinexor, bortezomib, dexamethasone (SVd)'
         </a>
         .)
        </p>
        <p>
        </p>
        <p>
         We consider four-drug regimens for patients with highly aggressive disease.
        </p>
        <p class="headingAnchor" id="H1387072113">
         <span class="h1">
          PENTA-REFRACTORY DISEASE
         </span>
         <span class="headingEndMark">
          —
         </span>
         For patients with penta-refractory disease, we typically offer therapies that target the B cell maturation antigen (BCMA) or alkylator-containing regimens before offering other therapies  (
         <a class="graphic graphic_algorithm graphicRef134484" href="/z/d/graphic/134484.html" rel="external">
          algorithm 1
         </a>
         ). These treatments have largely been studied in prospective, uncontrolled trials.
        </p>
        <p class="headingAnchor" id="H3171051638">
         <span class="h2">
          Targeting BCMA
         </span>
         <span class="headingEndMark">
          —
         </span>
         B cell maturation antigen (BCMA) is selectively expressed on differentiated plasma cells, including tumor cells in MM, and is thus an important therapeutic target in this disease  (
         <a class="graphic graphic_algorithm graphicRef134484" href="/z/d/graphic/134484.html" rel="external">
          algorithm 1
         </a>
         ). It can be targeted using chimeric antigen receptor (CAR)-T cells or a bispecific antibody targeting BCMA and CD3. In this setting, the CAR-T cell therapy with
         <a class="drug drug_general" data-topicid="131213" href="/z/d/drug information/131213.html" rel="external">
          idecabtagene vicleucel
         </a>
         (ide-cel) or
         <a class="drug drug_general" data-topicid="135088" href="/z/d/drug information/135088.html" rel="external">
          ciltacabtagene autoleucel
         </a>
         (cilta-cel) prolongs progression-free survival (PFS) when compared with standard chemotherapy regimens [
         <a href="#rid1">
          1,2
         </a>
         ]. Use of the other BCMA-directed therapies in relapsed MM is based on single-arm clinical trials evaluating the investigational agent. CAR-T cells must be manufactured for the individual patient, while bispecific antibodies are available as off-the-shelf treatments. The anti-BCMA antibody drug conjugate
         <a class="drug drug_general" data-topicid="129194" href="/z/d/drug information/129194.html" rel="external">
          belantamab mafodotin
         </a>
         was withdrawn from the market in the United States, although it remains accessible through the manufacturer for patients who started treatment prior to its withdrawal and is still available in Europe based on conditional European Medicines Agency (EMA) approval.
        </p>
        <p>
         Small case series suggest that MM refractory to one anti-BCMA therapy may not be refractory to another, although the preferred sequencing of therapies is unclear [
         <a href="#rid3">
          3,4
         </a>
         ]. As an example, in a series of 20 patients with relapsed MM who had prior treatment with an anti-BCMA antibody, treatment with the CAR-T cell therapy cilta-cel resulted in an overall response rate of 60 percent and a median duration of response of 11 months [
         <a href="#rid3">
          3
         </a>
         ]. However, some patients with MM progressing after a BCMA-directed therapy will be resistant to other BCMA-directed therapies through various mechanisms, including genetic changes in the BCMA-encoding gene
         <em>
          TNFRSF17
         </em>
         , evolution of BCMA-negative clones with biallelic deletions of the TNFRSF17 locus, or selective expansion of pre-existing BCMA-negative clones [
         <a href="#rid5">
          5
         </a>
         ]. Further studies are needed to determine how to best incorporate mutational testing to guide treatment decisions.
        </p>
        <p class="headingAnchor" id="H3300407871">
         <span class="h3">
          Chimeric antigen receptor T cells
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Clinical use
         </strong>
         – The use of CAR-T cell therapy is individualized weighing disease tempo, availability of other treatments, and expected toxicity  (
         <a class="graphic graphic_algorithm graphicRef134484" href="/z/d/graphic/134484.html" rel="external">
          algorithm 1
         </a>
         ). While CAR-T therapy has substantial activity against relapsed or refractory MM, treatment is associated with significant toxicity, the manufacturing process is complex and expensive, and access to treatment is challenging.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Ide-cel and cilta-cel are BCMA-directed CAR-T therapies approved in the United States for relapsed or refractory MM following at least four lines of systemic therapy, including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 monoclonal antibody. Both are also approved in Europe. The prescribing information for ide-cel and cilta-cel carry warnings for cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS). Facilities that dispense this agent require special certification, and staff must be trained to recognize and manage these adverse events.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         CAR-T cells are generated from the patient's own T lymphocytes, which are genetically modified (transfected) with a gene that encodes a CAR to direct the patient's T cells against the MM cells. The T cells are genetically modified ex vivo, expanded in a production facility, and then infused back into the patient as therapy. Prior to reinfusion, patients receive a lymphodepleting chemotherapy preparative/conditioning regimen (ie,
         <a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">
          cyclophosphamide
         </a>
         plus
         <a class="drug drug_general" data-topicid="8452" href="/z/d/drug information/8452.html" rel="external">
          fludarabine
         </a>
         ).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Efficacy
         </strong>
         – Both ide-cel and cilta-cel have demonstrated efficacy in relapsed and refractory MM with high response rates and improved PFS over that seen with standard chemotherapy regimens, although with increased toxicity. They have not been directly compared with each other.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Ide-cel – Support for ide-cel after &gt;4 lines of prior therapy comes from a phase 2 study (KarMMa) of ide-cel following &gt;3 prior regimens that reported estimated median PFS and overall survival (OS) of 8.8 and 19.4 months, respectively [
         <a href="#rid6">
          6
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         Studies are investigating the benefit of ide-cel earlier in the disease course. In a multicenter, open-label phase 3 trial (KarMMa-3), 386 adults with MM who had received two to four prior regimens (including a proteasome inhibitor, an immunomodulatory agent, and
         <a class="drug drug_general" data-topicid="105443" href="/z/d/drug information/105443.html" rel="external">
          daratumumab
         </a>
         ) and who were refractory to the last regimen were randomly assigned in a 2:1 ratio to receive ide-cel or one of five standard chemotherapy regimens selected prior to randomization based on prior therapies and clinician discretion [
         <a href="#rid1">
          1
         </a>
         ]. Choices for standard chemotherapy were: daratumumab,
         <a class="drug drug_general" data-topicid="88099" href="/z/d/drug information/88099.html" rel="external">
          pomalidomide
         </a>
         ,
         <a class="drug drug_general" data-topicid="9334" href="/z/d/drug information/9334.html" rel="external">
          dexamethasone
         </a>
         (DPd); daratumumab,
         <a class="drug drug_general" data-topicid="8509" href="/z/d/drug information/8509.html" rel="external">
          bortezomib
         </a>
         , dexamethasone (DVd);
         <a class="drug drug_general" data-topicid="105607" href="/z/d/drug information/105607.html" rel="external">
          ixazomib
         </a>
         ,
         <a class="drug drug_general" data-topicid="9822" href="/z/d/drug information/9822.html" rel="external">
          lenalidomide
         </a>
         , dexamethasone (IRd);
         <a class="drug drug_general" data-topicid="86042" href="/z/d/drug information/86042.html" rel="external">
          carfilzomib
         </a>
         plus dexamethasone (Kd); and
         <a class="drug drug_general" data-topicid="105610" href="/z/d/drug information/105610.html" rel="external">
          elotuzumab
         </a>
         , pomalidomide, dexamethasone (Elo-Pd). After a median follow-up of 18.6 months, ide-cel resulted in deeper responses and superior PFS (median 13.3 versus 4.4 months; HR 0.49, 95% CI 0.38-0.65). OS data are immature.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Cilta-cel – Support for cilta-cel after &gt;4 lines of prior therapy comes from phase 2 studies of cilta-cel in heavily pretreated MM that reported estimated 27-month PFS and OS of approximately 55 and 70 percent, respectively (CARTITUDE-1 [
         <a href="#rid7">
          7,8
         </a>
         ] and CARTIFAN-1 [
         <a href="#rid9">
          9
         </a>
         ]).
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         Studies are also investigating the benefit of cilta-cel earlier in the disease course. In a subsequent multicenter, open-label phase 3 trial (CARTITUDE-4), 419 adults with lenalidomide-refractory MM after one to three prior lines of therapy (including a proteasome inhibitor and an immunomodulatory agent) were randomly assigned to receive cilta-cel or chemotherapy with either DPd or
         <a class="drug drug_general" data-topicid="88099" href="/z/d/drug information/88099.html" rel="external">
          pomalidomide
         </a>
         ,
         <a class="drug drug_general" data-topicid="8509" href="/z/d/drug information/8509.html" rel="external">
          bortezomib
         </a>
         , and
         <a class="drug drug_general" data-topicid="9334" href="/z/d/drug information/9334.html" rel="external">
          dexamethasone
         </a>
         (PVd) based on clinician's choice [
         <a href="#rid2">
          2
         </a>
         ]. After a median follow-up of 15.9 months, cilta-cel resulted in deeper responses and superior PFS (12-month PFS 76 versus 49 percent; HR 0.26, 95% CI 0.18-0.38). OS data are immature.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         The 208 patients assigned to cilta-cel received at least one cycle of bridging chemotherapy with DPd or PVd; the median time from apheresis to cilta-cel infusion was 79 days and 32 patients (15 percent) progressed or died before the infusion and were counted as PFS events, 20 of whom were able to receive cilta-cel as a subsequent line of therapy.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         A meta-analysis that included data from 950 patients undergoing CAR-T for MM reported a pooled response rate of 78 percent (95% CI 72-84 percent) [
         <a href="#rid10">
          10
         </a>
         ]. Median PFS ranged from 8 to 20 months.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Toxicity
         </strong>
         – CAR-T therapy can be associated with serious complications, including severe, and rarely fatal neurologic events and CRS, which is a systemic response to the activation and proliferation of CAR-T cells characterized by various symptoms including high fever, flu-like symptoms, and hypotension. Consensus-based guidance on the prevention and management of adverse events are available from the European Myeloma Network (EMN) [
         <a href="#rid11">
          11
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         In the KarMMa-3 trial of ide-cel versus standard chemotherapy, ide-cel resulted in more adverse events of grade 3 or 4 (93 versus 75 percent) and of grade 5 (14 versus 6 percent) [
         <a href="#rid1">
          1
         </a>
         ]. Those assigned to ide-cel had more infections of grade 3 or 4 (24 versus 18 percent) and grade 5 (4 versus 2 percent). CRS occurred in 197 patients (88 percent), of which a minority were grade 3 or 4 (9 patients, 4 percent) or grade 5 (2 patients, 1 percent). Neurologic events of any grade occurred in 34 patients (15 percent), seven (3 percent) were grade 3 or 4, and none were grade 5.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         In the CARTITUDE-4 trial of cilta-cel, there were 10 treatment-related deaths, seven of which were due to coronavirus disease 2019 (COVID-19) [
         <a href="#rid2">
          2
         </a>
         ]. CRS occurred in 76 percent (1 percent grade 3 or 4). CAR-T cell neurotoxicity occurred in 21 percent (2.8 percent grade 3 or 4).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         CRS is common and may be life-threatening, but it typically responds to treatment with aggressive supportive care that includes
         <a class="drug drug_general" data-topicid="10208" href="/z/d/drug information/10208.html" rel="external">
          tocilizumab
         </a>
         and corticosteroids. In the meta-analysis described above, the pooled grade 3 or 4 or higher CRS rate was 6.4 percent (95% CI 4-9 percent) and the pooled grade 3 or 4 ICANS rate was 3.5 percent (95% CI 2-5 percent) [
         <a href="#rid10">
          10
         </a>
         ]. CRS and ICANS are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/118012.html" rel="external">
          "Cytokine release syndrome (CRS)"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/129618.html" rel="external">
          "Immune effector cell-associated neurotoxicity syndrome (ICANS)"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Other adverse events include hypersensitivity reactions, serious infections [
         <a href="#rid12">
          12
         </a>
         ], prolonged cytopenias, prolonged hypogammaglobulinemia, hemophagocytic lymphohistiocytosis/macrophage activation syndrome [
         <a href="#rid13">
          13
         </a>
         ], effects on ability to drive and use machines, second malignancies (including potential T cell malignancies [
         <a href="#rid14">
          14
         </a>
         ]), Guillain-Barre syndrome, and a delayed-onset progressive movement disorder (ie, progressive parkinsonism). Delayed parkinsonism following BCMA-targeted CAR-T is discussed in more detail separately. (See
         <a class="medical medical_review" href="/z/d/html/129618.html" rel="external">
          "Immune effector cell-associated neurotoxicity syndrome (ICANS)", section on 'Delayed parkinsonism'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The US Food and Drug Administration has received reports of T cell malignancies in patients treated with BCMA-directed or CD19-directed autologous CAR-T cell immunotherapies [
         <a href="#rid14">
          14,15
         </a>
         ]. The overall benefits of these products continue to outweigh their potential risks for their approved uses, and so for most patients this information will not affect choice of therapy. However, this may be a consideration for clinical trials evaluating use of CAR-T in earlier stages of myeloma and lymphoma.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1548717220">
         <span class="h3">
          Bispecific antibodies
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Clinical use
         </strong>
         – The use of a bispecific antibody is individualized, weighing disease tempo, availability of other treatments, and expected toxicity  (
         <a class="graphic graphic_algorithm graphicRef134484" href="/z/d/graphic/134484.html" rel="external">
          algorithm 1
         </a>
         ). As an off-the-shelf treatment option, it may be preferred in rapidly progressing disease unlikely to be controlled while awaiting CAR-T cell manufacturing.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <a class="drug drug_general" data-topicid="139997" href="/z/d/drug information/139997.html" rel="external">
          Teclistamab
         </a>
         and
         <a class="drug drug_general" data-topicid="142431" href="/z/d/drug information/142431.html" rel="external">
          elranatamab
         </a>
         are bispecific monoclonal antibodies directed at both BCMA on the tumor and CD3 on the patient's T cells. They have demonstrated activity in heavily pretreated populations but have not been directly compared with other therapies  (
         <a class="graphic graphic_algorithm graphicRef134484" href="/z/d/graphic/134484.html" rel="external">
          algorithm 1
         </a>
         ) [
         <a href="#rid16">
          16-19
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Both
         <a class="drug drug_general" data-topicid="139997" href="/z/d/drug information/139997.html" rel="external">
          teclistamab
         </a>
         and
         <a class="drug drug_general" data-topicid="142431" href="/z/d/drug information/142431.html" rel="external">
          elranatamab
         </a>
         are approved in the United States for patients who have received at least four prior lines of therapy including an anti-CD38 monoclonal antibody, a proteasome inhibitor, and an immunomodulatory agent [
         <a href="#rid20">
          20,21
         </a>
         ]. The prescribing information for both warnings for CRS and neurologic toxicity, including ICANS. They are available through restricted risk evaluation and mitigation strategy (REMS) programs.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         They are administered subcutaneously in gradually increasing doses over the first week, followed by weekly dosing thereafter. Patients are closely monitored for at least 48 hours after each dose escalation.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Specific administration considerations are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/131450.html" rel="external">
          "Multiple myeloma: Administration considerations for common therapies", section on 'Bispecific antibodies'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Efficacy
         </strong>
         – BCMA-directed bispecific antibodies have demonstrated efficacy in relapsed and refractory MM with high response rates.
         <a class="drug drug_general" data-topicid="139997" href="/z/d/drug information/139997.html" rel="external">
          Teclistamab
         </a>
         and
         <a class="drug drug_general" data-topicid="142431" href="/z/d/drug information/142431.html" rel="external">
          elranatamab
         </a>
         have not been directly compared with each other or with other treatments.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Teclistamab
         </strong>
         – Support for
         <a class="drug drug_general" data-topicid="139997" href="/z/d/drug information/139997.html" rel="external">
          teclistamab
         </a>
         after &gt;4 lines of prior therapy comes from an open-label, single-arm phase 1/2 multicenter trial (MajesTEC-1) of teclistamab in 165 patients with relapsed or refractory MM who had received at least three prior therapies, including an anti-CD38 monoclonal antibody, a proteasome inhibitor, and an immunomodulatory agent, and who had not received prior BCMA-targeted therapy [
         <a href="#rid17">
          17,18
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         After a median follow-up of 14.1 months, the overall response rate was 63 percent, 65 patients (39 percent) had a complete response or better, and 44 patients (27 percent) had no measurable residual disease. Median time to first response was 1.2 months (range: 0.2 to 5.5 months).
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         The median duration of response was 18.4 months. Estimated median PFS was 11.3 months (95% CI 8.8-17.1 months). OS data was not mature, but the estimated median OS was 18.3 months (95% CI 15.1 months to not estimable).
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Elranatamab
         </strong>
         – Support for
         <a class="drug drug_general" data-topicid="142431" href="/z/d/drug information/142431.html" rel="external">
          elranatamab
         </a>
         after &gt;4 lines of prior therapy comes from a phase 2 study (MagnetisMM-3) of elranatamab in 123 patients with relapsed or refractory MM who had received at least three prior therapies, including an anti-CD38 monoclonal antibody, a proteasome inhibitor, and an immunomodulatory agent, and who had not received prior BCMA-targeted therapy [
         <a href="#rid19">
          19
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         After a median follow-up of 14.7 months, the overall response rate was 61 percent, 43 patients (35 percent) had a complete response or better, and 29 patients had no measurable residual disease. Median time to first response was 1.2 months (range: 0.9 to 7.4 months).
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         Estimated PFS at 15 months was 51 percent for the population as a whole and 90 percent for those achieving a complete response or better. OS data was not mature. Estimated OS at 15 months was 57 percent for the population as a whole and 93 percent for those achieving a complete response or better.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Toxicity
         </strong>
         – In addition to warnings about CRS and ICANS, the prescribing information for
         <a class="drug drug_general" data-topicid="139997" href="/z/d/drug information/139997.html" rel="external">
          teclistamab
         </a>
         and
         <a class="drug drug_general" data-topicid="142431" href="/z/d/drug information/142431.html" rel="external">
          elranatamab
         </a>
         includes warnings about hepatotoxicity, infections, neutropenia, hypersensitivity and other administration reactions, and embryo-fetal toxicity. Consensus-based guidance on the prevention and management of adverse events are available from the EMN [
         <a href="#rid11">
          11
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         In MajesTEC-1, 95 percent of patients treated with
         <a class="drug drug_general" data-topicid="139997" href="/z/d/drug information/139997.html" rel="external">
          teclistamab
         </a>
         experienced at least one grade 3 or 4 toxicity, with hematologic toxicity being most common [
         <a href="#rid18">
          18
         </a>
         ]. CRS occurred in 120 patients (73 percent), all but one of which were grade 1 or 2 [
         <a href="#rid22">
          22
         </a>
         ]. Neurologic toxicities were reported in 15 percent, all but one of which were grade 1 or 2.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Other nonhematologic toxicities occurring in 20 to 30 percent of cases included injection-site erythema, gastrointestinal toxicity, fatigue, fever, headache, arthralgia, and cough. Those occurring in 15 to 19 percent included pneumonia, COVID-19, bone pain, and back pain.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         In MagnetisMM-3, 71 percent of patients treated with
         <a class="drug drug_general" data-topicid="142431" href="/z/d/drug information/142431.html" rel="external">
          elranatamab
         </a>
         experienced at least one grade 3 or 4 toxicity, with hematologic and infectious toxicities being the most common [
         <a href="#rid19">
          19
         </a>
         ]. Infections occurred in 70 percent of patients; 40 percent were grade 3 or 4, and 6.5 percent were fatal. CRS occurred in 58 percent of patients, all of which were grade 1 or 2. Peripheral neuropathy was reported as motor dysfunction (17 percent) and sensory neuropathy (14 percent), with only one grade 3 peripheral neuropathy and no grade 4 or 5 events. ICANS occurred in 3.4 percent of patients (all grade 1 or 2).
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1776279996">
         <span class="h3">
          Belantamab mafodotin
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Clinical use
         </strong>
         –
         <a class="drug drug_general" data-topicid="129194" href="/z/d/drug information/129194.html" rel="external">
          Belantamab mafodotin
         </a>
         was withdrawn from the market in the United States, although it remains accessible through the manufacturer for patients who started treatment prior to its withdrawal and is still available in Europe based on conditional EMA approval [
         <a href="#rid23">
          23
         </a>
         ]. Belantamab mafodotin is an anti-BCMA humanized immunoglobulin G (IgG) antibody conjugated to the microtubular disrupting agent monomethyl auristatin.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <a class="drug drug_general" data-topicid="129194" href="/z/d/drug information/129194.html" rel="external">
          Belantamab mafodotin
         </a>
         had received accelerated approval in the United States and conditional approval from the EMA for patients who have received at least four prior therapies including an anti-CD38 monoclonal antibody, a proteasome inhibitor, and an immunomodulatory agent [
         <a href="#rid24">
          24
         </a>
         ]. Full approval was contingent upon confirmed clinical benefit in a phase 3 randomized trial.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Efficacy
         </strong>
         – Two uncontrolled open-label trials (DREAMM-1 and DREAMM-2) demonstrated positive response data with
         <a class="drug drug_general" data-topicid="129194" href="/z/d/drug information/129194.html" rel="external">
          belantamab mafodotin
         </a>
         in relapsed or refractory MM. However, initial results of a randomized phase 3 trial (DREAMM-3) of belantamab mafodotin versus
         <a class="drug drug_general" data-topicid="88099" href="/z/d/drug information/88099.html" rel="external">
          pomalidomide
         </a>
         and
         <a class="drug drug_general" data-topicid="9334" href="/z/d/drug information/9334.html" rel="external">
          dexamethasone
         </a>
         (Pd) in relapsed or refractory MM have not confirmed clinical benefit, leading to market withdrawal [
         <a href="#rid23">
          23
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         An open-label randomized trial (DREAMM-2) evaluated two dosing regimens of
         <a class="drug drug_general" data-topicid="129194" href="/z/d/drug information/129194.html" rel="external">
          belantamab mafodotin
         </a>
         in 196 patients with MM refractory to a proteasome inhibitor and an immunomodulatory agent, and refractory or intolerant to an anti-CD38 monoclonal antibody, with a median of seven lines of prior therapy (range 3 to 21) [
         <a href="#rid25">
          25
         </a>
         ]. After a median follow-up of approximately six months, the overall response rates (ORR) and median PFS times for the two groups were:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         2.5 mg/kg cohort – ORR 31 percent (30 of 97 patients), median PFS 2.9 months (95% CI 2.1-3.7)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         3.4 mg/kg cohort – ORR 34 percent (34 of 99 patients), median PFS 4.9 months (95% CI 2.3-6.2)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         In a smaller open-label, single-arm trial (DREAMM-1), responses to
         <a class="drug drug_general" data-topicid="129194" href="/z/d/drug information/129194.html" rel="external">
          belantamab mafodotin
         </a>
         (3.4 mg/kg) were noted in 21 of 35 patients (60 percent) with MM refractory to an immunomodulatory agent and a proteasome inhibitor [
         <a href="#rid26">
          26,27
         </a>
         ]. The median PFS was 12 months. On subgroup analysis, responses were lower among patients with prior exposure to
         <a class="drug drug_general" data-topicid="105443" href="/z/d/drug information/105443.html" rel="external">
          daratumumab
         </a>
         .
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Initial results from DREAMM-3 available through a company press release reported numerically longer observed median PFS with
         <a class="drug drug_general" data-topicid="129194" href="/z/d/drug information/129194.html" rel="external">
          belantamab mafodotin
         </a>
         versus Pd that did not reach statistical significance (11.2 versus 7 months; HR 1.03, 95% CI 0.72-1.47) [
         <a href="#rid28">
          28
         </a>
         ]. At a median follow-up time of approximately 11 months, median OS was similar in the two arms (21.2 versus 21.1 months; HR 1.14, 95% CI 0.77-1.68).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Toxicity
         </strong>
         –
         <a class="drug drug_general" data-topicid="129194" href="/z/d/drug information/129194.html" rel="external">
          Belantamab mafodotin
         </a>
         frequently results in changes in the corneal epithelium, resulting in corneal ulceration, visual loss, and symptoms including blurred vision and dry eyes [
         <a href="#rid24">
          24
         </a>
         ]. Most cases reverse with dose reductions or dose holds, and the ongoing use of
         <a class="drug drug_general" data-topicid="8660" href="/z/d/drug information/8660.html" rel="external">
          artificial tears
         </a>
         . Patients are advised to use preservative-free lubricant eye drops and to avoid contact lens use. Ophthalmic exams must be conducted at baseline, prior to each dose, and in the event of worsening symptoms. (See
         <a class="medical medical_review" href="/z/d/html/96203.html" rel="external">
          "Ocular side effects of systemically administered chemotherapy", section on 'Antibody-drug conjugates'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Other common nonhematologic adverse reactions include nausea, pyrexia, infusion-related reactions, and fatigue. Grade 3 or greater thrombocytopenia is seen in approximately one-third of patients treated with a dose of 3.4 mg/kg [
         <a href="#rid25">
          25
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2977013410">
         <span class="h2">
          Alkylator containing
         </span>
         <span class="headingEndMark">
          —
         </span>
         Regimens containing alkylators, such as
         <a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">
          cyclophosphamide
         </a>
         ,
         <a class="drug drug_general" data-topicid="9605" href="/z/d/drug information/9605.html" rel="external">
          melphalan
         </a>
         , and
         <a class="drug drug_general" data-topicid="9323" href="/z/d/drug information/9323.html" rel="external">
          bendamustine
         </a>
         are active in MM  (
         <a class="graphic graphic_algorithm graphicRef134484" href="/z/d/graphic/134484.html" rel="external">
          algorithm 1
         </a>
         ). It is important to note that patients who have not been treated with standard-dose melphalan- or cyclophosphamide-based chemotherapy can still benefit from these regimens even if they previously received autologous hematopoietic cell transplantation (HCT), which typically employs a single high-dose administration of melphalan [
         <a href="#rid29">
          29
         </a>
         ]. Melphalan-based therapy is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/6650.html" rel="external">
          "Multiple myeloma: Management in resource-limited settings"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H4225994934">
         <span class="h3">
          VDT-PACE
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Clinical use
         </strong>
         – The VDT-PACE regimen (
         <a class="drug drug_general" data-topicid="8509" href="/z/d/drug information/8509.html" rel="external">
          bortezomib
         </a>
         ,
         <a class="drug drug_general" data-topicid="9334" href="/z/d/drug information/9334.html" rel="external">
          dexamethasone
         </a>
         ,
         <a class="drug drug_general" data-topicid="10095" href="/z/d/drug information/10095.html" rel="external">
          thalidomide
         </a>
         ,
         <a class="drug drug_general" data-topicid="9271" href="/z/d/drug information/9271.html" rel="external">
          cisplatin
         </a>
         ,
         <a class="drug drug_general" data-topicid="9391" href="/z/d/drug information/9391.html" rel="external">
          doxorubicin
         </a>
         ,
         <a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">
          cyclophosphamide
         </a>
         , and
         <a class="drug drug_general" data-topicid="8430" href="/z/d/drug information/8430.html" rel="external">
          etoposide
         </a>
         ) is an intensive treatment option for patients with penta-refractory disease, usually as a bridge to additional therapies in patients with an adequate performance status  (
         <a class="graphic graphic_algorithm graphicRef134484" href="/z/d/graphic/134484.html" rel="external">
          algorithm 1
         </a>
         ).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Each cycle of VDT-PACE consists of subcutaneous
         <a class="drug drug_general" data-topicid="8509" href="/z/d/drug information/8509.html" rel="external">
          bortezomib
         </a>
         (1 mg/m
         <sup>
          2
         </sup>
         body surface area [BSA] on days 1, 4, 8, and 11), oral
         <a class="drug drug_general" data-topicid="9334" href="/z/d/drug information/9334.html" rel="external">
          dexamethasone
         </a>
         (40 mg/day on days 1, 2, 3 and 4), and oral
         <a class="drug drug_general" data-topicid="10095" href="/z/d/drug information/10095.html" rel="external">
          thalidomide
         </a>
         (200 mg daily at bedtime throughout the cycle) [
         <a href="#rid30">
          30
         </a>
         ]. The remaining drugs are given as continuous intravenous infusions on days 1 through 4 and include
         <a class="drug drug_general" data-topicid="9271" href="/z/d/drug information/9271.html" rel="external">
          cisplatin
         </a>
         (10 mg/m
         <sup>
          2
         </sup>
         BSA per day),
         <a class="drug drug_general" data-topicid="9391" href="/z/d/drug information/9391.html" rel="external">
          doxorubicin
         </a>
         (10 mg/m
         <sup>
          2
         </sup>
         BSA per day),
         <a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">
          cyclophosphamide
         </a>
         (400 mg/m
         <sup>
          2
         </sup>
         BSA per day), and
         <a class="drug drug_general" data-topicid="8430" href="/z/d/drug information/8430.html" rel="external">
          etoposide
         </a>
         (40 mg/m
         <sup>
          2
         </sup>
         BSA per day). Cycles are repeated at four- to six-week intervals as long as neutrophil and platelet counts are recovered, and other toxicities have resolved. Growth factor support with
         <a class="drug drug_general" data-topicid="8446" href="/z/d/drug information/8446.html" rel="external">
          filgrastim
         </a>
         or pegylated filgrastim is required.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The PACE is administered as a 24-hour infusion to maintain continuously high drug levels to target slowly dividing plasma cell clones and reduce the risk of doxorubicin-related cardiomyopathy. Specific administration considerations are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/131450.html" rel="external">
          "Multiple myeloma: Administration considerations for common therapies"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Efficacy
         </strong>
         – Initial data regarding VDT-PACE come from its use in the Total Therapy-3 protocol from the University of Arkansas in which it was given before and after tandem HCT [
         <a href="#rid31">
          31,32
         </a>
         ]. Additional data come from earlier Total Therapy protocols that used DT-PACE without
         <a class="drug drug_general" data-topicid="8509" href="/z/d/drug information/8509.html" rel="external">
          bortezomib
         </a>
         along with HCT [
         <a href="#rid33">
          33
         </a>
         ]. In these trials, VTD-PACE had high response rates, but assessment of response duration was confounded by the incorporation of HCT.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Efficacy outside of these protocols comes from small, single-center retrospective studies. As an example, a single-center retrospective analysis of 141 patients with relapsed refractory MM after a median of four prior therapies treated with VDT-PACE or a VDT-PACE-like regimen [
         <a href="#rid30">
          30
         </a>
         ]. An at least partial response (PR) was reported in 54 percent and very good PR (VGPR) or better in 10 percent. Median PFS was 3 months. Separate retrospective analyses of VD-PACE [
         <a href="#rid34">
          34
         </a>
         ], TD-PACE [
         <a href="#rid35">
          35,36
         </a>
         ], and VTD-PACE [
         <a href="#rid37">
          37
         </a>
         ] have reported median PFS up to 11 months.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Toxicity
         </strong>
         – Treatment with VDT-PACE is often associated with high incidence of therapy-related adverse events including severe cytopenias, neuropathy, and thromboembolic events. In one of the retrospective analyses described above, over half of patients receiving VDT-PACE required readmission for toxicity during cycle 1, including admissions for neutropenic fever (37 percent) and nephrotoxicity (15 percent).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Growth factor support with
         <a class="drug drug_general" data-topicid="8446" href="/z/d/drug information/8446.html" rel="external">
          filgrastim
         </a>
         or pegylated filgrastim is required. Prophylactic antimicrobial therapy is strongly recommended until white blood cell (WBC)/absolute neutrophil count (ANC) recovery. Antithrombotic prophylaxis and ulcer prophylaxis are also encouraged.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3232565042">
         <span class="h3">
          DCEP
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Clinical use
         </strong>
         – The DCEP regimen (
         <a class="drug drug_general" data-topicid="9334" href="/z/d/drug information/9334.html" rel="external">
          dexamethasone
         </a>
         ,
         <a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">
          cyclophosphamide
         </a>
         ,
         <a class="drug drug_general" data-topicid="8430" href="/z/d/drug information/8430.html" rel="external">
          etoposide
         </a>
         , and
         <a class="drug drug_general" data-topicid="9271" href="/z/d/drug information/9271.html" rel="external">
          cisplatin
         </a>
         ) is an intensive treatment option for patients with penta-refractory disease, usually as a bridge to additional therapies in patients with an adequate performance status  (
         <a class="graphic graphic_algorithm graphicRef134484" href="/z/d/graphic/134484.html" rel="external">
          algorithm 1
         </a>
         ).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         For each cycle of DCEP, treatment is administered on days 1 through 4 and includes a continuous intravenous infusion of
         <a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">
          cyclophosphamide
         </a>
         (400 mg/m
         <sup>
          2
         </sup>
         BSA per day),
         <a class="drug drug_general" data-topicid="9271" href="/z/d/drug information/9271.html" rel="external">
          cisplatin
         </a>
         (15 mg/m
         <sup>
          2
         </sup>
         BSA per day), and
         <a class="drug drug_general" data-topicid="8430" href="/z/d/drug information/8430.html" rel="external">
          etoposide
         </a>
         (40 mg/m
         <sup>
          2
         </sup>
         BSA per day), along with oral or intravenous
         <a class="drug drug_general" data-topicid="9334" href="/z/d/drug information/9334.html" rel="external">
          dexamethasone
         </a>
         (40 mg daily) [
         <a href="#rid38">
          38,39
         </a>
         ]. Cycles are repeated every 28 days as long as neutrophil and platelet counts are recovered, and other toxicities have resolved. Specific administration considerations are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/131450.html" rel="external">
          "Multiple myeloma: Administration considerations for common therapies"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Palliative radiation therapy has been administered safely in conjunction with DCEP [
         <a href="#rid40">
          40
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Efficacy
         </strong>
         – Data regarding efficacy of DCEP come from small studies. In a single-center prospective trial of DCEP in relapsed or refractory MM, responses were seen in 7 of 12 patients (two complete) and median response duration was 9 months (range 4 to 36 months) [
         <a href="#rid38">
          38
         </a>
         ]. In a retrospective study of DCEP in 52 patients with relapsed or refractory MM, and at least PR was reported in 27 patients (9 VGPR) [
         <a href="#rid37">
          37
         </a>
         ]. Median PFS was 3.8 months (95% CI 2.8-4.9 months).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Toxicity
         </strong>
         – In the trial described above, the main toxicities associated with DCEP were transient cytopenias that required granulocyte growth factor support [
         <a href="#rid38">
          38
         </a>
         ]. In the retrospective study, there was 6 percent treatment-related mortality [
         <a href="#rid37">
          37
         </a>
         ]. Common adverse events included increased transfusion requirement (62 percent), rehospitalization (29 percent), febrile neutropenia (29 percent), delay in treatment &gt;7 days (33 percent), and venous thromboembolism (6 percent). As with VDT-PACE, growth factor support with
         <a class="drug drug_general" data-topicid="8446" href="/z/d/drug information/8446.html" rel="external">
          filgrastim
         </a>
         or pegylated filgrastim is required and prophylactic antimicrobial therapy during WBC/ANC recovery is strongly recommended.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H4276500649">
         <span class="h3">
          Bendamustine
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Clinical use
         </strong>
         – Off-label
         <a class="drug drug_general" data-topicid="9323" href="/z/d/drug information/9323.html" rel="external">
          bendamustine
         </a>
         is used mainly in patients who have exhausted most other treatment options for myeloma but have adequate performance status  (
         <a class="graphic graphic_algorithm graphicRef134484" href="/z/d/graphic/134484.html" rel="external">
          algorithm 1
         </a>
         ).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <a class="drug drug_general" data-topicid="9323" href="/z/d/drug information/9323.html" rel="external">
          Bendamustine
         </a>
         can be administered as a doublet with a corticosteroid or in three-drug combinations such as bendamustine plus
         <a class="drug drug_general" data-topicid="8509" href="/z/d/drug information/8509.html" rel="external">
          bortezomib
         </a>
         and
         <a class="drug drug_general" data-topicid="9334" href="/z/d/drug information/9334.html" rel="external">
          dexamethasone
         </a>
         [
         <a href="#rid41">
          41
         </a>
         ]; bendamustine plus
         <a class="drug drug_general" data-topicid="9822" href="/z/d/drug information/9822.html" rel="external">
          lenalidomide
         </a>
         and dexamethasone [
         <a href="#rid42">
          42-44
         </a>
         ]; and bendamustine plus
         <a class="drug drug_general" data-topicid="88099" href="/z/d/drug information/88099.html" rel="external">
          pomalidomide
         </a>
         and dexamethasone [
         <a href="#rid45">
          45
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Efficacy
         </strong>
         – Data regarding the off-label use of
         <a class="drug drug_general" data-topicid="9323" href="/z/d/drug information/9323.html" rel="external">
          bendamustine
         </a>
         in relapsed MM come from small, single-arm studies. In a dose escalation study of single-agent bendamustine in 31 patients with relapsed MM, ORR was 55 percent with a PFS of eight months [
         <a href="#rid46">
          46
         </a>
         ]. A retrospective study of bendamustine plus
         <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">
          prednisone
         </a>
         in multiply relapsed MM reported an ORR of 30 percent with median PFS of 9.3 months [
         <a href="#rid47">
          47
         </a>
         ]. In other studies, responses were reported in 61 percent of patients following bendamustine plus
         <a class="drug drug_general" data-topicid="8509" href="/z/d/drug information/8509.html" rel="external">
          bortezomib
         </a>
         and
         <a class="drug drug_general" data-topicid="9334" href="/z/d/drug information/9334.html" rel="external">
          dexamethasone
         </a>
         [
         <a href="#rid41">
          41
         </a>
         ], 47 to 89 percent following bendamustine plus
         <a class="drug drug_general" data-topicid="9822" href="/z/d/drug information/9822.html" rel="external">
          lenalidomide
         </a>
         and dexamethasone [
         <a href="#rid42">
          42-44
         </a>
         ]; and 61 percent following bendamustine plus
         <a class="drug drug_general" data-topicid="88099" href="/z/d/drug information/88099.html" rel="external">
          pomalidomide
         </a>
         and dexamethasone [
         <a href="#rid45">
          45
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Toxicity
         </strong>
         – Most patients treated with bendamustine-containing regimens will have bone marrow suppression with neutropenia and thrombocytopenia [
         <a href="#rid46">
          46
         </a>
         ]. Other toxicities include nausea, vomiting, fatigue, diarrhea, constipation, anorexia, and hyperbilirubinemia. Rare but serious adverse events include severe, potentially fatal skin reactions, second cancers, progressive multifocal leukoencephalopathy, and anaphylaxis. Extravasation injury can occur.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3908626026">
         <span class="h2">
          Talquetamab
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patients with penta-refractory MM that is also refractory to alkylators and anti-BCMA therapies are encouraged to enroll on clinical trials. Outside of a clinical trial,
         <a class="drug drug_general" data-topicid="142419" href="/z/d/drug information/142419.html" rel="external">
          talquetamab
         </a>
         is one of our preferred options for this population based on high response rates in an uncontrolled trial  (
         <a class="graphic graphic_algorithm graphicRef134484" href="/z/d/graphic/134484.html" rel="external">
          algorithm 1
         </a>
         ). Talquetamab is also an alternative to the use of anti-BCMA therapies and alkylator-containing therapies in penta-refractory MM. However, there is more uncertainty regarding the administration, toxicities, and long-term efficacy of talquetamab compared with these other approaches.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Clinical use
         </strong>
         –
         <a class="drug drug_general" data-topicid="142419" href="/z/d/drug information/142419.html" rel="external">
          Talquetamab
         </a>
         is a bispecific monoclonal antibody directed at both GPRC5D on the tumor and CD3 on the patient's T cells. It has demonstrated activity in heavily pretreated populations but has not been directly compared with other therapies.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <a class="drug drug_general" data-topicid="142419" href="/z/d/drug information/142419.html" rel="external">
          Talquetamab
         </a>
         is approved in the United States for patients who have received at least four prior therapies, including an anti-CD38 monoclonal antibody, a proteasome inhibitor, and an immunomodulatory agent [
         <a href="#rid48">
          48
         </a>
         ]. The prescribing information for talquetamab carries warnings for CRS and neurologic toxicity, including ICANS. Talquetamab is available through a restricted REMS program.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <a class="drug drug_general" data-topicid="142419" href="/z/d/drug information/142419.html" rel="external">
          Talquetamab
         </a>
         is administered as a subcutaneous injection. Following initial step-up dosing, talquetamab can be administered at a dose of 0.4 mg/kg once weekly or 0.8 mg/kg every two weeks.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Efficacy
         </strong>
         – An open-label, phase 1/2 multicenter trial (MonumenTAL-1) evaluated
         <a class="drug drug_general" data-topicid="142419" href="/z/d/drug information/142419.html" rel="external">
          talquetamab
         </a>
         in patients with relapsed or refractory MM who had received at least three prior therapies, including an anti-CD38 monoclonal antibody, a proteasome inhibitor, and an immunomodulatory agent [
         <a href="#rid49">
          49
         </a>
         ]. Efficacy data were reported in the prescribing information for talquetamab [
         <a href="#rid48">
          48
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Among the 100 patients treated with two step-up doses followed by 0.4 mg/kg once weekly, the overall response rate was 73 percent (95% CI 63.2-81.4 percent), and the median duration of response was 9.5 months (95% CI 6.5 months to not evaluable) after a median follow-up of 14 months.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Among the 87 patients treated with three step-up doses followed by 0.8 mg/kg every two weeks, the overall response rate was 74 percent (95% CI 63-82 percent), and the median duration of response was not reached after a median follow-up of six months; 85 percent maintained a response for at least nine months.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Toxicity
         </strong>
         – In addition to warnings about CRS and ICANS, the prescribing information includes warnings about oral toxicity and weight loss, infections, cytopenias, skin toxicity, hepatotoxicity, and embryo-fetal toxicity. Consensus-based guidance on the prevention and management of adverse events are available from the EMN [
         <a href="#rid11">
          11
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Safety data come from a cohort of 339 patients treated with various doses of
         <a class="drug drug_general" data-topicid="142419" href="/z/d/drug information/142419.html" rel="external">
          talquetamab
         </a>
         on MonumenTAL-1 and are reported in the prescribing information for talquetamab along with recommendations for dose adjustment based on toxicity [
         <a href="#rid48">
          48
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         In MonumenTAL-1, 47 percent of patients experienced serious adverse reactions, 9 percent discontinued treatment due to an adverse reaction, and 3.2 percent had fatal adverse reactions.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Most adverse reactions were of grade 1 or 2. Nonhematologic toxicities occurring in ≥40 percent of patients included pyrexia, CRS, dysgeusia, nail disorders, musculoskeletal pain, skin disorders, and fatigue.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <a class="drug drug_general" data-topicid="142419" href="/z/d/drug information/142419.html" rel="external">
          Talquetamab
         </a>
         is associated with oral toxicity and weight loss in most patients. In MonumenTAL-1, 80 percent of patients experienced oral toxicity, and 2.1 percent had grade 3 oral toxicity. The most frequent oral toxicities were dysgeusia, dry mouth, dysphagia, ageusia, and stomatitis. Weight loss occurred in 62 percent of patients regardless of oral toxicity (weight loss ≥10 percent in 29 percent and ≥20 percent in 2.7 percent).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <a class="drug drug_general" data-topicid="142419" href="/z/d/drug information/142419.html" rel="external">
          Talquetamab
         </a>
         is associated with skin reactions and nail changes in most patients, which are most frequently grade 1 or 2, but may be severe. Skin reactions include maculopapular and erythematous rash, xerosis, pruritus, palmar-plantar erythrodysesthesia syndrome, and others. Nail changes include discoloration, dystrophy, hypertrophy, pitting, ridging, fissures, and others.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H4289133369">
         <span class="h2">
          Selinexor
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patients with penta-refractory MM that is also refractory to alkylators and anti-BCMA therapies are encouraged to enroll on clinical trials.
         <a class="drug drug_general" data-topicid="121843" href="/z/d/drug information/121843.html" rel="external">
          Selinexor
         </a>
         is an option outside of a clinical trial  (
         <a class="graphic graphic_algorithm graphicRef134484" href="/z/d/graphic/134484.html" rel="external">
          algorithm 1
         </a>
         ).
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Clinical use
         </strong>
         – The oral nuclear export inhibitor
         <a class="drug drug_general" data-topicid="121843" href="/z/d/drug information/121843.html" rel="external">
          selinexor
         </a>
         is approved in the US in combination with
         <a class="drug drug_general" data-topicid="9334" href="/z/d/drug information/9334.html" rel="external">
          dexamethasone
         </a>
         for the treatment of adults with relapsed refractory MM who have received at least four prior therapies and whose disease is resistant to several other forms of treatment, including at least two proteasome inhibitors, at least two immunomodulatory agents, and an anti-CD38 monoclonal antibody. It is also approved in combination with
         <a class="drug drug_general" data-topicid="8509" href="/z/d/drug information/8509.html" rel="external">
          bortezomib
         </a>
         and dexamethasone for all patients with relapsed MM.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Patients taking
         <a class="drug drug_general" data-topicid="121843" href="/z/d/drug information/121843.html" rel="external">
          selinexor
         </a>
         should receive antiemetic prophylaxis and be monitored for the development of thrombocytopenia, neutropenia, and hyponatremia [
         <a href="#rid50">
          50,51
         </a>
         ]. Patients taking selinexor should avoid taking other medications that might cause dizziness or confusion.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The combination of
         <a class="drug drug_general" data-topicid="121843" href="/z/d/drug information/121843.html" rel="external">
          selinexor
         </a>
         ,
         <a class="drug drug_general" data-topicid="8509" href="/z/d/drug information/8509.html" rel="external">
          bortezomib
         </a>
         , and
         <a class="drug drug_general" data-topicid="9334" href="/z/d/drug information/9334.html" rel="external">
          dexamethasone
         </a>
         is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/121127.html" rel="external">
          "Multiple myeloma: Treatment of first or second relapse", section on 'Selinexor, bortezomib, dexamethasone (SVd)'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Efficacy
         </strong>
         –
         <a class="drug drug_general" data-topicid="121843" href="/z/d/drug information/121843.html" rel="external">
          Selinexor
         </a>
         has been evaluated in single-arm studies in combination with other drugs in heavily pretreated populations [
         <a href="#rid52">
          52-56
         </a>
         ]. The following two phase 2 trials evaluated selinexor (80 mg) plus
         <a class="drug drug_general" data-topicid="9334" href="/z/d/drug information/9334.html" rel="external">
          dexamethasone
         </a>
         (20 mg), each administered twice weekly, in patients with multiply relapsed MM:
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         STORM Part 1 evaluated this combination in 48 patients refractory to
         <a class="drug drug_general" data-topicid="8509" href="/z/d/drug information/8509.html" rel="external">
          bortezomib
         </a>
         ,
         <a class="drug drug_general" data-topicid="86042" href="/z/d/drug information/86042.html" rel="external">
          carfilzomib
         </a>
         ,
         <a class="drug drug_general" data-topicid="9822" href="/z/d/drug information/9822.html" rel="external">
          lenalidomide
         </a>
         , and
         <a class="drug drug_general" data-topicid="88099" href="/z/d/drug information/88099.html" rel="external">
          pomalidomide
         </a>
         (ie, quad-refractory) and 31 patients also refractory to an anti-CD38 antibody (ie, penta-refractory) [
         <a href="#rid54">
          54
         </a>
         ]. The ORR was 21 percent and responses were seen in 6 of 17 patients with high-risk cytogenetics. The median duration of response was five months.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         STORM Part 2 evaluated this combination in 122 patients with prior exposure to
         <a class="drug drug_general" data-topicid="8509" href="/z/d/drug information/8509.html" rel="external">
          bortezomib
         </a>
         ,
         <a class="drug drug_general" data-topicid="86042" href="/z/d/drug information/86042.html" rel="external">
          carfilzomib
         </a>
         ,
         <a class="drug drug_general" data-topicid="9822" href="/z/d/drug information/9822.html" rel="external">
          lenalidomide
         </a>
         ,
         <a class="drug drug_general" data-topicid="88099" href="/z/d/drug information/88099.html" rel="external">
          pomalidomide
         </a>
         ,
         <a class="drug drug_general" data-topicid="105443" href="/z/d/drug information/105443.html" rel="external">
          daratumumab
         </a>
         , and an alkylating agent, with disease refractory to at least one proteasome inhibitor, one immunomodulatory agent, and daratumumab (ie, triple-refractory) [
         <a href="#rid56">
          56
         </a>
         ]. The ORR was 26 percent. The median duration of response was 4.4 months. Quality of life worsened with treatment, as measured using scales for physical well-being, functional well-being, and myeloma-specific measures [
         <a href="#rid57">
          57
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Toxicity
         </strong>
         – In STORM Part 1, the most common grade 3 or higher toxicities were thrombocytopenia (59 percent), anemia (28 percent), neutropenia (23 percent), hyponatremia (22 percent), leukopenia (15 percent), and fatigue (15 percent) [
         <a href="#rid54">
          54
         </a>
         ]. Common less severe toxicities included nausea, vomiting, diarrhea, and infections. All patients received antiemetic prophylaxis with a 5-HT3 receptor antagonist.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         In STORM Part 2, toxicity led to treatment interruption or dose modification in 80 percent of patients and permanent treatment discontinuation in 18 percent [
         <a href="#rid56">
          56
         </a>
         ]. There were 12 deaths due to adverse events. Supportive care included granulocyte colony-stimulating factors, thrombopoietin-receptor agonists, nutritional support, appetite stimulants, psychostimulants, and antiemetic agents.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Better outcomes with less toxicity may be achieved with careful attention to supportive care and dose reductions at the onset of toxicity [
         <a href="#rid58">
          58
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H4061716778">
         <span class="h1">
          SPECIAL POPULATIONS
         </span>
        </p>
        <p class="headingAnchor" id="H4108434806">
         <span class="h2">
          Venetoclax for MM with t(11;14)
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Clinical use
         </strong>
         – Although it is not yet approved for this indication, the BCL-2 inhibitor
         <a class="drug drug_general" data-topicid="107696" href="/z/d/drug information/107696.html" rel="external">
          venetoclax
         </a>
         has demonstrated substantial activity in MM with t(11;14), and we thus consider off-label use of venetoclax alone or in combination as a late line of treatment for patients with t(11;14) who have limited treatment options or as an earlier line of treatment in patients with t(11;14) who have highly aggressive disease refractory to initial treatment  (
         <a class="graphic graphic_algorithm graphicRef134484" href="/z/d/graphic/134484.html" rel="external">
          algorithm 1
         </a>
         ). We do
         <strong>
          not
         </strong>
         offer venetoclax to other patients with MM, regardless of BCL-2 expression. We do not use BCL-2 expression to guide therapy as it is difficult to measure, and testing is not standardized.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <a class="drug drug_general" data-topicid="107696" href="/z/d/drug information/107696.html" rel="external">
          Venetoclax
         </a>
         can be administered as a single agent, but it is most often given in combination with a proteasome inhibitor (
         <a class="drug drug_general" data-topicid="8509" href="/z/d/drug information/8509.html" rel="external">
          bortezomib
         </a>
         or
         <a class="drug drug_general" data-topicid="86042" href="/z/d/drug information/86042.html" rel="external">
          carfilzomib
         </a>
         ) plus
         <a class="drug drug_general" data-topicid="9334" href="/z/d/drug information/9334.html" rel="external">
          dexamethasone
         </a>
         . Trials are evaluating other combinations, including the combination of
         <a class="drug drug_general" data-topicid="105443" href="/z/d/drug information/105443.html" rel="external">
          daratumumab
         </a>
         plus bortezomib and dexamethasone [
         <a href="#rid59">
          59
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Efficacy and toxicity
         </strong>
         – A phase 3, placebo controlled trial (BELLINI) evaluated the addition of
         <a class="drug drug_general" data-topicid="107696" href="/z/d/drug information/107696.html" rel="external">
          venetoclax
         </a>
         to
         <a class="drug drug_general" data-topicid="8509" href="/z/d/drug information/8509.html" rel="external">
          bortezomib
         </a>
         plus
         <a class="drug drug_general" data-topicid="9334" href="/z/d/drug information/9334.html" rel="external">
          dexamethasone
         </a>
         in patients with relapsed or refractory MM [
         <a href="#rid60">
          60
         </a>
         ]. While venetoclax deepened responses and improved median progression-free survival (PFS), the trial was stopped early because of an increased risk of death with venetoclax, including eight treatment-emergent fatal infections, which resulted in inferior overall survival (OS; hazard ratio [HR] 2.03, 95% CI 1.04-3.95). The initial trial protocol required herpes simplex virus prophylaxis; a protocol amendment added mandatory antibacterial prophylaxis and PJP pneumonia prophylaxis. In contrast, prespecified subgroup analyses suggested improved PFS without a clear decrease in survival among 35 patients with t(11;14) (PFS HR 0.11, 95% CI 0.02-0.56 and OS HR 0.34, 95% CI 0.03-3.84) and 95 patients with high BCL-2 gene expression (PFS HR 0.50, 95% CI 0.29-0.86 and OS HR 1.45; 95% CI 0.57-3.68). These results suggested that the venetoclax plus bortezomib and dexamethasone regimen is associated with excess morbidity and mortality as compared with bortezomib and dexamethasone in the general population of patients with relapsed or refractory MM, but that the combination is effective in patients with t(11;14) [
         <a href="#rid60">
          60-63
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         A dose-escalation phase 2 study evaluated
         <a class="drug drug_general" data-topicid="107696" href="/z/d/drug information/107696.html" rel="external">
          venetoclax
         </a>
         ,
         <a class="drug drug_general" data-topicid="86042" href="/z/d/drug information/86042.html" rel="external">
          carfilzomib
         </a>
         , and
         <a class="drug drug_general" data-topicid="9334" href="/z/d/drug information/9334.html" rel="external">
          dexamethasone
         </a>
         in 49 patients with relapsed or refractory MM [
         <a href="#rid64">
          64
         </a>
         ]. The overall response rate (ORR) was 80 percent, and the complete response (CR) rate was 41 percent. Of the 13 patients with t(11;14), best response was at least a very good partial response (VGPR) in 11 patients, with 7 achieving a CR. There were no dose limiting toxicities. The most common toxicities were diarrhea (65 percent), fatigue (47 percent), and nausea (47 percent). Grade 3 or 4 toxicities included hypertension (16 percent) and pneumonia (12 percent). Other toxicities included other infections, acute kidney injury, congestive heart failure, and hypoxia.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3831686754">
         <span class="h2">
          Frail patients
         </span>
         <span class="headingEndMark">
          —
         </span>
         When possible, we prefer three-drug regimens over two-drug regimens. Indeed, many older adults were included in the trials that evaluated three-drug regimens and demonstrated superiority over two-drug regimens. However, two-drug regimens are an acceptable alternative for frail patients who are unable to tolerate three-drug regimens. These are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/121127.html" rel="external">
          "Multiple myeloma: Treatment of first or second relapse", section on 'Frail patients'
         </a>
         .)
        </p>
        <p>
         Anti-CD38 monoclonal antibodies and high-dose steroids are sometimes administered as single agents.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Daratumumab
         </strong>
         – The anti-CD38 monoclonal antibody
         <a class="drug drug_general" data-topicid="105443" href="/z/d/drug information/105443.html" rel="external">
          daratumumab
         </a>
         is approved as a single agent in the United States for patients who have received at least three prior lines of therapy including a proteasome inhibitor and an immunomodulatory drug or who are double-refractory to a proteasome inhibitor and an immunomodulatory drug. Specific administration considerations for daratumumab are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/131450.html" rel="external">
          "Multiple myeloma: Administration considerations for common therapies", section on 'Anti-CD38 monoclonal antibodies'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Several non-randomized studies have evaluated the efficacy and safety of single-agent
         <a class="drug drug_general" data-topicid="105443" href="/z/d/drug information/105443.html" rel="external">
          daratumumab
         </a>
         [
         <a href="#rid65">
          65-69
         </a>
         ]. In a combined analysis of two open-label, multicenter, phase 2 trials (SIRIUS and GEN501), 148 patients with multiply relapsed MM (median of five prior therapies) were treated with daratumumab (16 mg/kg, weekly for eight weeks, then every two weeks for 16 weeks, then monthly until progression) [
         <a href="#rid69">
          69
         </a>
         ]. Treatment was well tolerated. Infusion reactions (mostly mild) were common with the first infusion and uncommon with subsequent infusions. The ORR was 30 percent (7 CR, 13 VGPR, 24 PR) with a median time to first response of one month. The estimated median duration of response and OS rates were 8 and 20 months, respectively. These rates compared favorably with expected outcomes in this population.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Given the increasing use of
         <a class="drug drug_general" data-topicid="105443" href="/z/d/drug information/105443.html" rel="external">
          daratumumab
         </a>
         as an earlier line of treatment, including as part of induction therapy in many instances, single-agent daratumumab as treatment of advanced myeloma that is resistant to multiple agents is now less commonly employed.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          High-dose steroids
         </strong>
         – High-dose steroids (eg, intravenous
         <a class="drug drug_general" data-topicid="9639" href="/z/d/drug information/9639.html" rel="external">
          methylprednisolone
         </a>
         ) can be useful in patients who have organ dysfunction, poor performance status, or low blood counts due to MM.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H467394247">
         <span class="h2">
          Resource-poor settings
         </span>
         <span class="headingEndMark">
          —
         </span>
         Access to preferred three-drug regimens is limited in certain areas of the world by age restrictions or resource limitations. Patients in such settings can still benefit from the use of treatment regimens that are based on alkylating agents (eg,
         <a class="drug drug_general" data-topicid="9605" href="/z/d/drug information/9605.html" rel="external">
          melphalan
         </a>
         or
         <a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">
          cyclophosphamide
         </a>
         ) and/or first-generation immunomodulatory agents (eg,
         <a class="drug drug_general" data-topicid="10095" href="/z/d/drug information/10095.html" rel="external">
          thalidomide
         </a>
         ). Details regarding the use of these regimens and guidance regarding the choice of regimen are provided separately. (See
         <a class="medical medical_review" href="/z/d/html/6650.html" rel="external">
          "Multiple myeloma: Management in resource-limited settings"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3940925716">
         <span class="h1">
          SOCIETY GUIDELINE LINKS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/114824.html" rel="external">
          "Society guideline links: Multiple myeloma"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3376950147">
         <span class="h1">
          INFORMATION FOR PATIENTS
         </span>
         <span class="headingEndMark">
          —
         </span>
         UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5
         <sup>
          th
         </sup>
         to 6
         <sup>
          th
         </sup>
         grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10
         <sup>
          th
         </sup>
         to 12
         <sup>
          th
         </sup>
         grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.
        </p>
        <p>
         Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient education" and the keyword(s) of interest.)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Basics topics (see
         <a class="medical medical_basics" href="/z/d/html/15531.html" rel="external">
          "Patient education: Multiple myeloma (The Basics)"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Beyond the Basics topics (see
         <a class="medical medical_patient" href="/z/d/html/688.html" rel="external">
          "Patient education: Multiple myeloma symptoms, diagnosis, and staging (Beyond the Basics)"
         </a>
         and
         <a class="medical medical_patient" href="/z/d/html/690.html" rel="external">
          "Patient education: Multiple myeloma treatment (Beyond the Basics)"
         </a>
         and
         <a class="medical medical_patient" href="/z/d/html/686.html" rel="external">
          "Patient education: Hematopoietic cell transplantation (bone marrow transplantation) (Beyond the Basics)"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3112683125">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          General principles
         </strong>
         – There are many approved treatment combinations for patients with relapsed and/or refractory multiple myeloma (MM). Most patients experience serial relapses over time and will ultimately receive most if not all available agents at some point during their disease course. Accompanying tables provide active drugs by class  (
         <a class="graphic graphic_table graphicRef121137" href="/z/d/graphic/121137.html" rel="external">
          table 1
         </a>
         ) and major toxicities of selected treatment regimens  (
         <a class="graphic graphic_table graphicRef108257" href="/z/d/graphic/108257.html" rel="external">
          table 2
         </a>
         ). General principles for treatment are provided separately. (See
         <a class="medical medical_review" href="/z/d/html/6643.html" rel="external">
          "Multiple myeloma: Overview of management", section on 'General principles'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Assess drug sensitivity
         </strong>
         – The choice of therapy for relapsed MM is influenced significantly by prior therapies received, response to those therapies, and likelihood of the disease being refractory to specific agents. In general, refractory disease is defined as progressing on or within 60 days of receiving standard doses of a specific therapy. (See
         <a class="local">
          'Assess drug sensitivity'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The term penta-refractory disease is used for MM refractory to all of the following:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         An anti-CD38 monoclonal antibody (eg, daratumumab, isatuximab)
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Lenalidomide
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Pomalidomide
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Bortezomib
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Carfilzomib
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The drugs that define penta-refractory MM are some of our most active agents in MM, and the regulatory approval of several other therapies has been limited to this specific population. Our approach is therefore structured according to whether or not the patient has penta-refractory MM.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Non-penta-refractory disease
         </strong>
         – For most patients with MM in third or greater relapse who maintain sensitivity to at least one of the agents listed above, we suggest a regimen that includes these agents rather than therapies used for penta-refractory disease (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). The choice of regimen is similar to that in first or second relapse, and it is driven by understanding of drug sensitivity and expected toxicity  (
         <a class="graphic graphic_algorithm graphicRef134483" href="/z/d/graphic/134483.html" rel="external">
          algorithm 2
         </a>
         ). (See
         <a class="local">
          'Non-penta-refractory disease'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Penta-refractory disease
         </strong>
         – For patients with penta-refractory disease, we suggest therapies that target BCMA or alkylator-containing regimens rather than other therapies  (
         <a class="graphic graphic_algorithm graphicRef134484" href="/z/d/graphic/134484.html" rel="external">
          algorithm 1
         </a>
         ) (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). (See
         <a class="local">
          'Targeting BCMA'
         </a>
         above and
         <a class="local">
          'Alkylator containing'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Patients with penta-refractory MM that is also refractory to alkylators and anti-BCMA therapies are encouraged to enroll on clinical trials. Outside of a clinical trial,
         <a class="drug drug_general" data-topicid="142419" href="/z/d/drug information/142419.html" rel="external">
          talquetamab
         </a>
         ,
         <a class="drug drug_general" data-topicid="121843" href="/z/d/drug information/121843.html" rel="external">
          selinexor
         </a>
         , and
         <a class="drug drug_general" data-topicid="107696" href="/z/d/drug information/107696.html" rel="external">
          venetoclax
         </a>
         are our preferred options for this population. (See
         <a class="local">
          'Talquetamab'
         </a>
         above and
         <a class="local">
          'Selinexor'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The BCL-2 inhibitor
         <a class="drug drug_general" data-topicid="107696" href="/z/d/drug information/107696.html" rel="external">
          venetoclax
         </a>
         has demonstrated activity in MM with t(11;14), and we consider off-label use of venetoclax alone or in combination for patients with t(11;14) who have limited alternatives either due to multiply refractory disease or comorbidities. We do
         <strong>
          not
         </strong>
         offer venetoclax to other patients with MM, regardless of BCL-2 expression. (See
         <a class="local">
          'Venetoclax for MM with t(11;14)'
         </a>
         above.)
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Rodriguez-Otero P, Ailawadhi S, Arnulf B, et al. Ide-cel or Standard Regimens in Relapsed and Refractory Multiple Myeloma. N Engl J Med 2023; 388:1002.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           San-Miguel J, Dhakal B, Yong K, et al. Cilta-cel or Standard Care in Lenalidomide-Refractory Multiple Myeloma. N Engl J Med 2023; 389:335.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cohen AD, Mateos MV, Cohen YC, et al. Efficacy and safety of cilta-cel in patients with progressive multiple myeloma after exposure to other BCMA-targeting agents. Blood 2023; 141:219.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Van Oekelen O, Nath K, Mouhieddine TH, et al. Interventions and outcomes of patients with multiple myeloma receiving salvage therapy after BCMA-directed CAR T therapy. Blood 2023; 141:756.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lee H, Ahn S, Maity R, et al. Mechanisms of antigen escape from BCMA- or GPRC5D-targeted immunotherapies in multiple myeloma. Nat Med 2023; 29:2295.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Munshi NC, Anderson LD Jr, Shah N, et al. Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma. N Engl J Med 2021; 384:705.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Berdeja JG, Madduri D, Usmani SZ, et al. Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study. Lancet 2021; 398:314.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Martin T, Usmani SZ, Berdeja JG, et al. Ciltacabtagene Autoleucel, an Anti-B-cell Maturation Antigen Chimeric Antigen Receptor T-Cell Therapy, for Relapsed/Refractory Multiple Myeloma: CARTITUDE-1 2-Year Follow-Up. J Clin Oncol 2023; 41:1265.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mi JQ, Zhao W, Jing H, et al. Phase II, Open-Label Study of Ciltacabtagene Autoleucel, an Anti-B-Cell Maturation Antigen Chimeric Antigen Receptor-T-Cell Therapy, in Chinese Patients With Relapsed/Refractory Multiple Myeloma (CARTIFAN-1). J Clin Oncol 2023; 41:1275.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mohyuddin GR, Rooney A, Balmaceda N, et al. Chimeric antigen receptor T-cell therapy in multiple myeloma: a systematic review and meta-analysis of 950 patients. Blood Adv 2021; 5:1097.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ludwig H, Terpos E, van de Donk N, et al. Prevention and management of adverse events during treatment with bispecific antibodies and CAR T cells in multiple myeloma: a consensus report of the European Myeloma Network. Lancet Oncol 2023; 24:e255.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kambhampati S, Sheng Y, Huang CY, et al. Infectious complications in patients with relapsed refractory multiple myeloma after BCMA CAR T-cell therapy. Blood Adv 2022; 6:2045.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kennedy VE, Wong C, Huang CY, et al. Macrophage activation syndrome-like (MAS-L) manifestations following BCMA-directed CAR T cells in multiple myeloma. Blood Adv 2021; 5:5344.
          </a>
         </li>
         <li class="breakAll">
          BCMA-Directed or CD19-Directed Autologous Chimeric Antigen Receptor (CAR) T cell Immunotherapies: FDA Investigating Serious Risk of T-cell Malignancy. US Food and Drug Administration, 2023. Available at: https://www.fda.gov/safety/medical-product-safety-information/bcma-directed-or-cd19-directed-autologous-chimeric-antigen-receptor-car-t-cell-immunotherapies-fda (Accessed on December 01, 2023).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nelson R. FDA investigating safety risks in CAR T-cell recipients. Lancet 2023; 402:2181.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pillarisetti K, Powers G, Luistro L, et al. Teclistamab is an active T cell-redirecting bispecific antibody against B-cell maturation antigen for multiple myeloma. Blood Adv 2020; 4:4538.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Usmani SZ, Garfall AL, van de Donk NWCJ, et al. Teclistamab, a B-cell maturation antigen × CD3 bispecific antibody, in patients with relapsed or refractory multiple myeloma (MajesTEC-1): a multicentre, open-label, single-arm, phase 1 study. Lancet 2021; 398:665.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Moreau P, Garfall AL, van de Donk NWCJ, et al. Teclistamab in Relapsed or Refractory Multiple Myeloma. N Engl J Med 2022; 387:495.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lesokhin AM, Tomasson MH, Arnulf B, et al. Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results. Nat Med 2023; 29:2259.
          </a>
         </li>
         <li class="breakAll">
          teclistamab-cqyv. United States prescribing information. Revised October 2022. US Food and Drug Administration. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/761291s000lbl.pdf (Accessed on October 27, 2022).
         </li>
         <li class="breakAll">
          elranatamab-bcmm. United States prescribing information. Revised August 2023. US Food and Drug Administration. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/761345s000lbl.pdf (Accessed on August 18, 2023).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Martin TG, Mateos MV, Nooka A, et al. Detailed overview of incidence and management of cytokine release syndrome observed with teclistamab in the MajesTEC-1 study of patients with relapsed/refractory multiple myeloma. Cancer 2023; 129:2035.
          </a>
         </li>
         <li class="breakAll">
          Dear Health Care Provider Letter (Blenrep). GSK. Available at: https://www.blenrep.com/content/dam/cf-pharma/dsa-blenrepv3/en_US/pdf/Blenrep-(belantamab-mafodotin-blmf)DearHCPLetterNov2022.pdf (Accessed on November 28, 2022).
         </li>
         <li class="breakAll">
          Belantamab mafodotin-blmf for injection. United States prescribing information. Revised August 2020. US Food and Drug Administration. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761158s000lbl.pdf (Accessed on August 07, 2020).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lonial S, Lee HC, Badros A, et al. Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study. Lancet Oncol 2020; 21:207.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Trudel S, Lendvai N, Popat R, et al. Targeting B-cell maturation antigen with GSK2857916 antibody-drug conjugate in relapsed or refractory multiple myeloma (BMA117159): a dose escalation and expansion phase 1 trial. Lancet Oncol 2018; 19:1641.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Trudel S, Lendvai N, Popat R, et al. Antibody-drug conjugate, GSK2857916, in relapsed/refractory multiple myeloma: an update on safety and efficacy from dose expansion phase I study. Blood Cancer J 2019; 9:37.
          </a>
         </li>
         <li class="breakAll">
          GSK provides update on DREAMM-3 phase III trial for Blenrep in relapsed/refractory multiple myeloma. GSK. Available at: https://www.gsk.com/en-gb/media/press-releases/gsk-provides-update-on-dreamm-3-phase-iii-trial-for-blenrep/ (Accessed on November 28, 2022).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Trieu Y, Trudel S, Pond GR, et al. Weekly cyclophosphamide and alternate-day prednisone: an effective, convenient, and well-tolerated oral treatment for relapsed multiple myeloma after autologous stem cell transplantation. Mayo Clin Proc 2005; 80:1578.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lakshman A, Singh PP, Rajkumar SV, et al. Efficacy of VDT PACE-like regimens in treatment of relapsed/refractory multiple myeloma. Am J Hematol 2018; 93:179.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Barlogie B, Anaissie E, van Rhee F, et al. Incorporating bortezomib into upfront treatment for multiple myeloma: early results of total therapy 3. Br J Haematol 2007; 138:176.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pineda-Roman M, Zangari M, Haessler J, et al. Sustained complete remissions in multiple myeloma linked to bortezomib in total therapy 3: comparison with total therapy 2. Br J Haematol 2008; 140:625.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lee CK, Barlogie B, Munshi N, et al. DTPACE: an effective, novel combination chemotherapy with thalidomide for previously treated patients with myeloma. J Clin Oncol 2003; 21:2732.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Abdallah AO, Sigle M, Mohyuddin GR, et al. Outcomes of VD-PACE With Immunomodulatory Agent as a Salvage Therapy for Relapsed/Refractory Multiple Myeloma. Clin Lymphoma Myeloma Leuk 2021; 21:e220.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Huynh T, Corre E, Lemonnier MP, et al. Role of D(T)PACE-based regimens as treatment of multiple myeloma with extramedullary relapse or refractory disease. Leuk Lymphoma 2021; 62:2235.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ainley L, Chavda SJ, Counsell N, et al. DT-PACE/ESHAP chemotherapy regimens as salvage therapy for multiple myeloma prior to autologous stem cell transplantation. Br J Haematol 2021; 192:e73.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Griffin PT, Ho VQ, Fulp W, et al. A comparison of salvage infusional chemotherapy regimens for recurrent/refractory multiple myeloma. Cancer 2015; 121:3622.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dadacaridou M, Papanicolaou X, Maltesas D, et al. Dexamethasone, cyclophosphamide, etoposide and cisplatin (DCEP) for relapsed or refractory multiple myeloma patients. J BUON 2007; 12:41.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Park S, Lee SJ, Jung CW, et al. DCEP for relapsed or refractory multiple myeloma after therapy with novel agents. Ann Hematol 2014; 93:99.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nehlsen AD, Sindhu KK, Moshier E, et al. The Safety and Efficacy of Radiation Therapy with Concurrent Dexamethasone, Cyclophosphamide, Etoposide, and Cisplatin-Based Systemic Therapy for Multiple Myeloma. Clin Lymphoma Myeloma Leuk 2022; 22:192.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ludwig H, Kasparu H, Leitgeb C, et al. Bendamustine-bortezomib-dexamethasone is an active and well-tolerated regimen in patients with relapsed or refractory multiple myeloma. Blood 2014; 123:985.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kumar SK, Krishnan A, LaPlant B, et al. Bendamustine, lenalidomide, and dexamethasone (BRD) is highly effective with durable responses in relapsed multiple myeloma. Am J Hematol 2015; 90:1106.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mey UJ, Brugger W, Schwarb H, et al. Bendamustine, lenalidomide and dexamethasone (BRd) has high activity as 2nd -line therapy for relapsed and refractory multiple myeloma - a phase II trial. Br J Haematol 2017; 176:770.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pozzi S, Gentile M, Sacchi S, et al. Bendamustine, Low-dose dexamethasone, and lenalidomide (BdL) for the treatment of patients with relapsed/refractory multiple myeloma confirms very promising results in a phase I/II study. Leuk Lymphoma 2017; 58:552.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sivaraj D, Green MM, Kang Y, et al. Bendamustine, pomalidomide, and dexamethasone for relapsed and/or refractory multiple myeloma. Blood Cancer J 2018; 8:71.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Knop S, Straka C, Haen M, et al. The efficacy and toxicity of bendamustine in recurrent multiple myeloma after high-dose chemotherapy. Haematologica 2005; 90:1287.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Damaj G, Malard F, Hulin C, et al. Efficacy of bendamustine in relapsed/refractory myeloma patients: results from the French compassionate use program. Leuk Lymphoma 2012; 53:632.
          </a>
         </li>
         <li class="breakAll">
          talquetamab-tgvs. United States prescribing information. Revised August 2023. US Food and Drug Administration. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/761342s000lbl.pdf (Accessed on August 11, 2023).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chari A, Minnema MC, Berdeja JG, et al. Talquetamab, a T-Cell-Redirecting GPRC5D Bispecific Antibody for Multiple Myeloma. N Engl J Med 2022; 387:2232.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gavriatopoulou M, Chari A, Chen C, et al. Integrated safety profile of selinexor in multiple myeloma: experience from 437 patients enrolled in clinical trials. Leukemia 2020; 34:2430.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mikhael J, Noonan KR, Faiman B, et al. Consensus Recommendations for the Clinical Management of Patients With Multiple Myeloma Treated With Selinexor. Clin Lymphoma Myeloma Leuk 2020; 20:351.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bahlis NJ, Sutherland H, White D, et al. Selinexor plus low-dose bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma. Blood 2018; 132:2546.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jakubowiak AJ, Jasielec JK, Rosenbaum CA, et al. Phase 1 study of selinexor plus carfilzomib and dexamethasone for the treatment of relapsed/refractory multiple myeloma. Br J Haematol 2019; 186:549.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vogl DT, Dingli D, Cornell RF, et al. Selective Inhibition of Nuclear Export With Oral Selinexor for Treatment of Relapsed or Refractory Multiple Myeloma. J Clin Oncol 2018; 36:859.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chen C, Siegel D, Gutierrez M, et al. Safety and efficacy of selinexor in relapsed or refractory multiple myeloma and Waldenstrom macroglobulinemia. Blood 2018; 131:855.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chari A, Vogl DT, Gavriatopoulou M, et al. Oral Selinexor-Dexamethasone for Triple-Class Refractory Multiple Myeloma. N Engl J Med 2019; 381:727.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chakraborty R, Efficace F. Importance of quality of life in early phase clinical trials: A case study of selinexor in multiple myeloma. Br J Haematol 2020; 189:e112.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chari A, Florendo E, Mancia IS, et al. Optimal Supportive Care With Selinexor Improves Outcomes in Patients With Relapsed/Refractory Multiple Myeloma. Clin Lymphoma Myeloma Leuk 2021; 21:e975.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bahlis NJ, Baz R, Harrison SJ, et al. Phase I Study of Venetoclax Plus Daratumumab and Dexamethasone, With or Without Bortezomib, in Patients With Relapsed or Refractory Multiple Myeloma With and Without t(11;14). J Clin Oncol 2021; 39:3602.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kumar SK, Harrison SJ, Cavo M, et al. Venetoclax or placebo in combination with bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma (BELLINI): a randomised, double-blind, multicentre, phase 3 trial. Lancet Oncol 2020; 21:1630.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kumar S, Kaufman JL, Gasparetto C, et al. Efficacy of venetoclax as targeted therapy for relapsed/refractory t(11;14) multiple myeloma. Blood 2017; 130:2401.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Moreau P, Chanan-Khan A, Roberts AW, et al. Promising efficacy and acceptable safety of venetoclax plus bortezomib and dexamethasone in relapsed/refractory MM. Blood 2017; 130:2392.
          </a>
         </li>
         <li class="breakAll">
          FDA Warns about the risks associated with the investigational use of Venclexta in Multiple Myeloma. https://www.fda.gov/Drugs/DrugSafety/ucm634120.htm (Accessed on March 25, 2019).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Costa LJ, Davies FE, Monohan GP, et al. Phase 2 study of venetoclax plus carfilzomib and dexamethasone in patients with relapsed/refractory multiple myeloma. Blood Adv 2021; 5:3748.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Botta C, Ciliberto D, Rossi M, et al. Network meta-analysis of randomized trials in multiple myeloma: efficacy and safety in relapsed/refractory patients. Blood Adv 2017; 1:455.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lokhorst HM, Plesner T, Laubach JP, et al. Targeting CD38 with Daratumumab Monotherapy in Multiple Myeloma. N Engl J Med 2015; 373:1207.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lonial S, Weiss BM, Usmani SZ, et al. Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial. Lancet 2016; 387:1551.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Usmani SZ, Weiss BM, Plesner T, et al. Clinical efficacy of daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma. Blood 2016; 128:37.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Usmani SZ, Nahi H, Plesner T, et al. Daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma: final results from the phase 2 GEN501 and SIRIUS trials. Lancet Haematol 2020; 7:e447.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 131449 Version 20.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36762851" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Ide-cel or Standard Regimens in Relapsed and Refractory Multiple Myeloma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/37272512" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Cilta-cel or Standard Care in Lenalidomide-Refractory Multiple Myeloma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36095849" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Efficacy and safety of cilta-cel in patients with progressive multiple myeloma after exposure to other BCMA-targeting agents.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36327160" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Interventions and outcomes of patients with multiple myeloma receiving salvage therapy after BCMA-directed CAR T therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/37653344" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Mechanisms of antigen escape from BCMA- or GPRC5D-targeted immunotherapies in multiple myeloma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33626253" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34175021" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35658469" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Ciltacabtagene Autoleucel, an Anti-B-cell Maturation Antigen Chimeric Antigen Receptor T-Cell Therapy, for Relapsed/Refractory Multiple Myeloma: CARTITUDE-1 2-Year Follow-Up.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36269898" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Phase II, Open-Label Study of Ciltacabtagene Autoleucel, an Anti-B-Cell Maturation Antigen Chimeric Antigen Receptor-T-Cell Therapy, in Chinese Patients With Relapsed/Refractory Multiple Myeloma (CARTIFAN-1).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33606005" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Chimeric antigen receptor T-cell therapy in multiple myeloma: a systematic review and meta-analysis of 950 patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/37269857" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Prevention and management of adverse events during treatment with bispecific antibodies and CAR T cells in multiple myeloma: a consensus report of the European Myeloma Network.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34543400" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Infectious complications in patients with relapsed refractory multiple myeloma after BCMA CAR T-cell therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34644387" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Macrophage activation syndrome-like (MAS-L) manifestations following BCMA-directed CAR T cells in multiple myeloma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34644387" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Macrophage activation syndrome-like (MAS-L) manifestations following BCMA-directed CAR T cells in multiple myeloma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/38071978" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : FDA investigating safety risks in CAR T-cell recipients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32956453" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Teclistamab is an active T cell-redirecting bispecific antibody against B-cell maturation antigen for multiple myeloma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34388396" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Teclistamab, a B-cell maturation antigen × CD3 bispecific antibody, in patients with relapsed or refractory multiple myeloma (MajesTEC-1): a multicentre, open-label, single-arm, phase 1 study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35661166" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Teclistamab in Relapsed or Refractory Multiple Myeloma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/37582952" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/37582952" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/37582952" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36991547" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Detailed overview of incidence and management of cytokine release syndrome observed with teclistamab in the MajesTEC-1 study of patients with relapsed/refractory multiple myeloma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36991547" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Detailed overview of incidence and management of cytokine release syndrome observed with teclistamab in the MajesTEC-1 study of patients with relapsed/refractory multiple myeloma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36991547" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Detailed overview of incidence and management of cytokine release syndrome observed with teclistamab in the MajesTEC-1 study of patients with relapsed/refractory multiple myeloma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31859245" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30442502" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Targeting B-cell maturation antigen with GSK2857916 antibody-drug conjugate in relapsed or refractory multiple myeloma (BMA117159): a dose escalation and expansion phase 1 trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30894515" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Antibody-drug conjugate, GSK2857916, in relapsed/refractory multiple myeloma: an update on safety and efficacy from dose expansion phase I study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30894515" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Antibody-drug conjugate, GSK2857916, in relapsed/refractory multiple myeloma: an update on safety and efficacy from dose expansion phase I study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16342650" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Weekly cyclophosphamide and alternate-day prednisone: an effective, convenient, and well-tolerated oral treatment for relapsed multiple myeloma after autologous stem cell transplantation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29067723" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Efficacy of VDT PACE-like regimens in treatment of relapsed/refractory multiple myeloma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17593024" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Incorporating bortezomib into upfront treatment for multiple myeloma: early results of total therapy 3.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18302711" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Sustained complete remissions in multiple myeloma linked to bortezomib in total therapy 3: comparison with total therapy 2.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12860952" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : DTPACE: an effective, novel combination chemotherapy with thalidomide for previously treated patients with myeloma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33093009" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Outcomes of VD-PACE With Immunomodulatory Agent as a Salvage Therapy for Relapsed/Refractory Multiple Myeloma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33792474" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Role of D(T)PACE-based regimens as treatment of multiple myeloma with extramedullary relapse or refractory disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33236352" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : DT-PACE/ESHAP chemotherapy regimens as salvage therapy for multiple myeloma prior to autologous stem cell transplantation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26149422" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : A comparison of salvage infusional chemotherapy regimens for recurrent/refractory multiple myeloma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17436400" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Dexamethasone, cyclophosphamide, etoposide and cisplatin (DCEP) for relapsed or refractory multiple myeloma patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24240976" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : DCEP for relapsed or refractory multiple myeloma after therapy with novel agents.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34736880" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : The Safety and Efficacy of Radiation Therapy with Concurrent Dexamethasone, Cyclophosphamide, Etoposide, and Cisplatin-Based Systemic Therapy for Multiple Myeloma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24227817" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Bendamustine-bortezomib-dexamethasone is an active and well-tolerated regimen in patients with relapsed or refractory multiple myeloma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26331432" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Bendamustine, lenalidomide, and dexamethasone (BRD) is highly effective with durable responses in relapsed multiple myeloma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27983764" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Bendamustine, lenalidomide and dexamethasone (BRd) has high activity as 2nd -line therapy for relapsed and refractory multiple myeloma - a phase II trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27442600" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Bendamustine, Low-dose dexamethasone, and lenalidomide (BdL) for the treatment of patients with relapsed/refractory multiple myeloma confirms very promising results in a phase I/II study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30065277" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : Bendamustine, pomalidomide, and dexamethasone for relapsed and/or refractory multiple myeloma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16154860" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : The efficacy and toxicity of bendamustine in recurrent multiple myeloma after high-dose chemotherapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21916831" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : Efficacy of bendamustine in relapsed/refractory myeloma patients: results from the French compassionate use program.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21916831" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : Efficacy of bendamustine in relapsed/refractory myeloma patients: results from the French compassionate use program.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36507686" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : Talquetamab, a T-Cell-Redirecting GPRC5D Bispecific Antibody for Multiple Myeloma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32094461" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : Integrated safety profile of selinexor in multiple myeloma: experience from 437 patients enrolled in clinical trials.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32245742" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : Consensus Recommendations for the Clinical Management of Patients With Multiple Myeloma Treated With Selinexor.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30352784" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : Selinexor plus low-dose bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31124580" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : Phase 1 study of selinexor plus carfilzomib and dexamethasone for the treatment of relapsed/refractory multiple myeloma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29381435" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : Selective Inhibition of Nuclear Export With Oral Selinexor for Treatment of Relapsed or Refractory Multiple Myeloma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29203585" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : Safety and efficacy of selinexor in relapsed or refractory multiple myeloma and Waldenstrom macroglobulinemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31433920" id="rid55" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          56 : Oral Selinexor-Dexamethasone for Triple-Class Refractory Multiple Myeloma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32080829" id="rid56" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          57 : Importance of quality of life in early phase clinical trials: A case study of selinexor in multiple myeloma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34404623" id="rid57" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          58 : Optimal Supportive Care With Selinexor Improves Outcomes in Patients With Relapsed/Refractory Multiple Myeloma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34388020" id="rid58" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          59 : Phase I Study of Venetoclax Plus Daratumumab and Dexamethasone, With or Without Bortezomib, in Patients With Relapsed or Refractory Multiple Myeloma With and Without t(11;14).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33129376" id="rid59" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          60 : Venetoclax or placebo in combination with bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma (BELLINI): a randomised, double-blind, multicentre, phase 3 trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29018077" id="rid60" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          61 : Efficacy of venetoclax as targeted therapy for relapsed/refractory t(11;14) multiple myeloma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28847998" id="rid61" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          62 : Promising efficacy and acceptable safety of venetoclax plus bortezomib and dexamethasone in relapsed/refractory MM.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28847998" id="rid62" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          63 : Promising efficacy and acceptable safety of venetoclax plus bortezomib and dexamethasone in relapsed/refractory MM.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34470049" id="rid63" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          64 : Phase 2 study of venetoclax plus carfilzomib and dexamethasone in patients with relapsed/refractory multiple myeloma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29296961" id="rid64" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          65 : Network meta-analysis of randomized trials in multiple myeloma: efficacy and safety in relapsed/refractory patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26308596" id="rid65" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          66 : Targeting CD38 with Daratumumab Monotherapy in Multiple Myeloma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26778538" id="rid66" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          67 : Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27216216" id="rid67" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          68 : Clinical efficacy of daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32470437" id="rid68" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          69 : Daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma: final results from the phase 2 GEN501 and SIRIUS trials.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
